Skip to main content

First Gene-Editing Therapies for Sickle Cell Disease, Casgevy and Lyfgenia, Approved by FDA

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 9, 2023.

By Physician’s Briefing Staff HealthDay Reporter

FRIDAY, Dec. 8, 2023 -- Two milestone gene therapies for sickle cell disease have been approved by the U.S. Food and Drug Administration.

Casgevy is the first medicine available in the United States to treat a genetic disease using the CRISPR gene-editing technique. The one-time treatment permanently changes DNA in a patient's blood cells, freeing them from the excruciating symptoms of sickle cell disease for life. The other approved therapy, Lyfgenia, uses a common virus to deliver genetic modifications to a patient's blood stem cells in their bone marrow.

In both therapies, stem cells are removed from a patient's blood for treatment. With Casgevy, CRISPR gene-editing technology knocks out a gene that triggers the development of defective, crescent-shaped blood cells. Meanwhile, medicine kills off flawed blood-producing cells in patients, who are then given back their own altered stem cells. The same thing happens with Lyfgenia, only a virus is used to deliver a genetic payload that causes the blood cells to start producing healthy hemoglobin. The genetically modified blood stem cells are then given back to the patient as a one-time, single-dose infusion.

Evidence supporting the approval of Casgevy was from a study of 44 patients treated with the gene-editing process. Out of 31 patients with sufficient follow-up time to be evaluated, 29 had complete freedom from the severe pain and organ damage that can occur during a sickle cell exacerbation. Furthermore, no patients experienced graft failure or graft rejection. Approval of Lyfgenia was supported by a 24-month study in which 32 patients received the therapy. Of those, 28 had no sickle cell events following their transplant.

Approval of Casgevy and Lyfgenia was granted to Vertex Pharmaceuticals and Bluebird Bio, respectively.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

Crude Sickle Cell Birth Prevalence 28.54 per 10,000 in Non-Hispanic Blacks

MONDAY, April 1, 2024 -- The crude sickle cell disease (SCD) birth prevalence is 28.54 per 10,000 non-Hispanic Black newborns, according to research published in the March 28...

Many Children With Sickle Cell Anemia Do Not Meet Quality Indicators

MONDAY, March 18, 2024 -- A number of children with sickle cell anemia (SCA) have low rates of receipt of recommended antibiotic prophylaxis and annual transcranial Doppler (TCD)...

Annual Indirect Economic Burden of Sickle Cell Disease Over $2 Million

WEDNESDAY, March 13, 2024 -- Adults with sickle cell disease (SCD) are more likely to report employment loss, and caregivers of children with SCD report more missed days of work...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.